- Research article
- Open Access
Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy
Biological Research volume 53, Article number: 22 (2020)
Duchenne muscular dystrophy (DMD) is a devastating genetic muscular disorder with no effective treatment that is caused by the loss of dystrophin. Human induced pluripotent stem cells (hiPSCs) offer a promising unlimited resource for cell-based therapies of muscular dystrophy. However, their clinical applications are hindered by inefficient myogenic differentiation, and moreover, the engraftment of non-transgene hiPSC-derived myogenic progenitors has not been examined in the mdx mouse model of DMD.
We investigated the muscle regenerative potential of myogenic progenitors derived from hiPSCs in mdx mice. The hiPSCs were transfected with enhanced green fluorescent protein (EGFP) vector and defined as EGFP hiPSCs. Myogenic differentiation was performed on EGFP hiPSCs with supplementary of basic fibroblast growth factor, forskolin, 6-bromoindirubin-3′-oxime as well as horse serum. EGFP hiPSCs-derived myogenic progenitors were engrafted into mdx mice via both intramuscular and intravenous injection. The restoration of dystrophin expression, the ratio of central nuclear myofibers, and the transplanted cells-derived satellite cells were accessed after intramuscular and systemic transplantation.
We report that abundant myogenic progenitors can be generated from hiPSCs after treatment with these three small molecules, with consequent terminal differentiation giving rise to mature myotubes in vitro. Upon intramuscular or systemic transplantation into mdx mice, these myogenic progenitors engrafted and contributed to human-derived myofiber regeneration in host muscles, restored dystrophin expression, ameliorated pathological lesions, and seeded the satellite cell compartment in dystrophic muscles.
This study demonstrates the muscle regeneration potential of myogenic progenitors derived from hiPSCs using non-transgenic induction methods. Engraftment of hiPSC-derived myogenic progenitors could be a potential future therapeutic strategy to treat DMD in a clinical setting.
Duchenne muscular dystrophy (DMD) (OMIM: 310200) is the most common form of inherited muscular dystrophy characterized by progressive skeletal muscle weakness and hypertrophy. It is a lethal X-linked recessive disease caused by mutations in dystrophin gene (DMD) (HGNC ID: 2928) [1, 2]. Dystrophin is a fundamental component of the dystrophin-associated glycoprotein complex in the sarcolemma that supports the stabilization of muscle fibers . The absence of dystrophin leads to myofiber damage during muscle contraction resulting in the excessive regeneration of satellite cells and fibrotic connective tissue [3, 4]. Satellite cells are adult stem cells capable of self-renewal and myogenic differentiation. They are located between the sarcolemma and basal lamina of muscle fibers, and are distinguished by expression of paired-box transcription factor 7 (Pax7) and Pax3 [5,6,7]. In dystrophic muscles, the reduplicative degenerative and regenerative processes exhaust satellite cells leading to the replacement of muscle cells with resident fibrosis and adipose tissue. Notably, recent studies show that dystrophin deficiency leads to impairments in cell polarity, proliferation, and myogenic differentiation of satellite cells, and eventually impairs muscle regenerative processes [8, 9].
Currently, there are no effective therapeutic strategies for patients with DMD apart from symptomatic treatments such as the application of corticosteroids to delay disease progression . Considering the evidence that muscle cell death and functional loss are strongly associated with dysfunction of satellite cells in DMD , transplantation of healthy satellite cells carrying a functional dystrophin gene may ameliorate muscle regeneration and self-renewal to maintain the satellite cell pool and restore dystrophin. Myoblasts served as the initial cell type candidate for replacement therapies of DMD because of the ease of accessibility in vitro . Researchers have shown that transplantation of myoblasts from healthy donors partially contribute to regeneration of skeletal muscles and restore dystrophin expression in dystrophic mice as well as patients with DMD [12,13,14,15]. However, their decreased proliferative potential during culture in vitro, limited migrated capacity, and poor survival after transplantation, greatly compromise their application in clinical therapies . Other adult stem cells, like bone marrow-derived side population (SP) cells , CD133+ cells [18, 19], mesoangioblasts , and adipose-derived stem cells (ADSCs) [21, 22], are reported to participate in regeneration of skeletal muscles after transplantation into dystrophic mouse or other animal models. Nevertheless, these multi-lineage stem cells display reduced proliferative potential when isolated from tissues and expanded in vitro, again limiting the required number of transplanted cells needed for therapy [6, 23, 24].
Induced pluripotent stem cells (iPSCs) share a similar self-renewal capability and pluripotency to embryonic stem cells (ESCs) [25, 26], providing an unlimited cell resource that is tailored to the specific patient for cell replacement therapy [27, 28]. In fact, autologous transplantation accompanied by decreased potential immune rejection, and transgene-free iPSC lines generated by advanced reprogramming methods without genome-integrating risk, have been showed to be more suitable for clinical cell therapy . Several investigators have generated myogenic progenitors and multinucleated myotubes from mouse and human iPSCs through diverse differentiation strategies [28, 30,31,32,33]. To improve the myogenic differentiation efficiency, inducible expression of MyoD and Pax3/Pax7 was utilized in several studies to enhance myogenic induction [32, 34, 35]. Darabi et al. demonstrated that the use of ectopic expression of Pax7 in human and mouse iPSCs produces robust myogenic progenitors in vitro, which successfully engrafted to produce dystrophin-positive myofibers, resulting in functional improvements in dystrophic mice . However, the safety of cell transplantation therapy using transgenic iPSC-derived myogenic progenitors limits their use for DMD therapy. Alternatively, the use of several small molecules has been shown to dramatically enhance myogenic progenitor generation derived from iPSCs. Researchers demonstrated that various combinations of small molecules like glycogen synthase kinase-3β (GSK-3β) inhibitor, forskolin, basic fibroblast growth factor (bFGF), and bone morphogenic protein (BMP) inhibitor, promote iPSCs to undergo myogenic differentiation in a high efficiency [36,37,38,39]. Nevertheless, the muscle regenerative capability of these iPSC-derived myogenic precursors induced by small molecules has not been assessed in dystrophic mouse models.
In the present study, we describe the direct derivation of skeletal myogenic progenitors from healthy human iPSCs (hiPSCs) using the three small molecules, GSK-3β inhibitor 6-bromoindirubin-3′-oxime (BIO), forskolin, and bFGF, to generate myotubes. Upon transplantation into mdx mice, we found that these hiPSC-derived myogenic progenitors contributed to long-term muscle regeneration and restored dystrophin expression.
The generation of hiPSCs from a healthy control donor was performed as previously described . Peripheral blood mononuclear cells from healthy control donor were collected for iPSC induction. Cells were transduced with the integration-free CytoTune-iPS Sendai Reprogramming Kit (Life Technologies, Carlsbad, CA, USA), which utilizes Sendai virus particles of the four factors (OCT4, SOX2, c-MYC, and KLF4). Transduced cells were plated on vitronectin-coated culture dishes and fed iPSC medium, which was replaced by StemPro 34 SFM (Life Technologies) from days 3 to 7. On day 7, the medium was replaced by feeder-free mTeSR1medium (STEMCELL Technologies, Vancouver, BC, Canada) until small colonies were formed. The growth of small colonies was maintained for another 3–4 weeks, and cell colonies were manually picked and mechanically dissociated for the first four passages. The hiPSCs were maintained on Matrigel-coated plates (BD Bioscience, Franklin Lakes, NJ, USA) with mTeSR1 medium (STEMCELL Technologies), and passaged every 4–5 days using 1 mg/mL dispase (Life Technologies). All experimental protocols including human stem cell use were approved by the Ethics Committee at the First Affiliated Hospital of Sun Yat-sen University.
Generation of enhanced green fluorescent protein (EGFP) transgenic hiPSCs
Following the Gateway LR reaction protocol, the entry clones pUp-EF1α and pDown-EGFP were cloned into the expression vector pDes-Puro to generate an expression lentiviral vector (pLV/Final-Puro-EF1α-EGFP). The lentiviral vectors were co-transfected with packaging plasmids into 293FT cells using the X-tremeGENE Transfection Reagent (Roche, Basel, Switzerland). After 48 h, the supernatant containing lentivirus was collected, filtered through a 0.45 μm filter and concentrated by ultracentrifugation. Stable enhanced green fluorescent protein (EGFP) transgenic hiPSCs (defined as EGFP hiPSCs) were generated by lentiviral transduction after a 12 h exposure to viral particles. Next, clones of EGFP hiPSCs were selectively isolated using 1 μg/mL puromycin (Sigma-Aldrich, St. Louis, MO, USA) in culture medium for 2 weeks.
All animal experiments were performed according to approved protocols by the Animal Care and Experimentation Committee of Sun Yat-sen University. NOD SCID (NOD.Cg-Prkdcscid/Nju) mice, C57 (C57BL/6J) mice, and mdx mice (C57BL/10ScSn-DMDmdx/J) were purchased from the Nanjing Biomedical Research Institute of Nanjing University (Nanjing, China). Five-to-eight-week-old NOD SCID mice were used for teratoma formation experiments, while C57 mice were used to detect dystrophin expression and 6–8-week-old male mdx mice were used for transplantation studies with EGFP hiPSC-derived myogenic progenitors.
Embryoid bodies and teratoma formation
For in vitro formation of embryoid bodies (EBs), EGFP hiPSCs were digested into small clumps using 1 mg/mL dispase (Life Technologies) and plated onto low adherent petri dishes (Greiner Bio-One, Monroe, NC, USA). EBs were cultured in suspension with Essential 6 medium (Life Technologies) for 7 days with media changes every other day. At day 8, EBs were plated onto gelatin-coated plates to allow adherent culture. After an additional 7 days, the EBs were fixed and immunofluorescence assays were performed to assess three germ layer formation markers.
For teratoma formation in vivo, EGFP hiPSCs from one 6-well plate were suspended in a 1:1 mixture of Dulbecco’s Modified Eagle’s medium (DMEM) (Life Technologies) and Matrigel matrix, and injected into NOD SCID mice subcutaneously. After 8–10 weeks, teratomas were dissected and paraffin-embedded tissue sections were subjected to hematoxylin and eosin staining for germ layer histological evaluation.
In vitro myogenic differentiation of EGFP hiPSCs
Differentiation of EGFP hiPSCs into myogenic progenitors and subsequent myotubes was performed using described protocols . Briefly, hiPSCs were dissociated using 1 mg/mL dispase and plated onto low adherent petri dishes to generate EBs. The EBs were maintained in suspension culture for 7 days with a myogenic induction medium consisting of STEMDiff APEL medium (STEMCELL Technologies) supplemented with 10 ng/mL bFGF (Life Technologies), 0.5 mM BIO (Santa Cruz Biotechnology, Dallas, TX, USA), and 20 mM forskolin (Santa Cruz Biotechnology). At day 8, EBs were transferred to Matrigel-coated plates to facilitate attachment over a 3-day period. The myogenic induction medium was then switched to DMEM containing 2% horse serum (Life Technologies) for an additional 26 days of terminal myogenic differentiation with a medium change every other day.
Transplantation of EGFP hiPSC-derived myogenic progenitors
Before intramuscular and intravenous transplantation, mdx mice were intraperitoneally injected with a daily dose of 20 mg/kg Busulfex (Otsuka, Tokyo, Japan) for 5 days to induce immunosuppression. The EGFP hiPSC-derived myogenic progenitors at differentiation (day 14) were used as donor cells. For intramuscular transplantation, 1 × 106 cells in 50 μL phosphate-buffered saline (PBS) (Hyclone, Logan, UT, USA) were injected into the left tibialis anterior (TA) muscle, while the right TA muscle received the same volume of PBS as a control. In addition, a group of mdx mice received the equivalent volume of PBS in both TA muscles to serve as additional negative controls. At 4, 8, and 12 weeks after transplantation, cell-injected left TA muscles, PBS-injected right TA muscles, and both TA muscles in negative control mdx mice (n = 3 for each group at each time point) were biopsied and frozen using isopentane cooled in liquid nitrogen for further immunofluorescence analyses. For intravenous transplantation, 2 × 106 cells in 200 μL PBS were injected into the tail vein of mdx mice, while a group of mdx mice were injected with the equivalent volume of PBS as negative controls. The TA muscles of cell-transplanted and PBS-injected mdx mice (n = 5 for each group) were harvested 8 weeks after transplantation for immunofluorescence studies.
Culture cells were fixed with 4% (w/v) paraformaldehyde (Sigma-Aldrich) for 15 min, permeabilized with 0.3% (v/v) Triton X-100 (Sigma-Aldrich) in PBS for 15 min, and then blocked with 5% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich) in PBS for 1 h at room temperature. Next, cell were incubated with primary antibodies diluted in 5% (w/v) BSA overnight at 4 °C. The following primary antibodies were used: OCT4 (1:100, Santa Cruz Biotechnology), SOX2 (1:200, Abcam, Cambridge, UK), TRA-1-60 (1:100, Merck Millipore, Billerica, MA, USA), TRA-1-81 (1:100, Merck Millipore), Nestin (1:200, Abcam), alpha 1 Fetoprotein (AFP) (1:100, Abcam), alpha smooth muscle actin (αSMA) (1:200, Abcam), PAX7 (1:100, Abcam), MYF5 (1:100, Abcam), Desmin (1:100, Abcam), MF20 for myosin heavy chain (MHC) (1:100, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA), and DYS1 (1:100, Leica Biosystems, Wetzlar, Germany). After primary antibody incubation, cells were washed three times with PBS and incubated at room temperature for 1 h with the corresponding Alexa Fluor 555-conjugated anti-mouse or anti-rabbit secondary antibody (1:1000, Cell Signaling Technology, Danvers, MA, USA). Nuclei were counter-stained with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). Images were captured using an IX71 fluorescence microscope (Olympus, Tokyo, Japan).
For tissue sections, serial 10-μm-thick cryosections of muscle tissues were collected, fixed with cold acetone for 10 min at 4 °C, and blocked with 10% (v/v) fetal bovine serum (FBS) and 2% horse serum for 1 h at room temperature. Sections were then incubated with primary antibodies against DYS1 (1:100, Leica Biosystems, Wetzlar, Germany), human spectrin (1:100, Abcam), GFP (1:100, Abcam), and Pax7 (1:100, Abcam) overnight at 4 °C. Tissue sections were washed three times with PBS and stained with Alexa Fluor 555-conjugated or Alexa Fluor 488-conjugated secondary antibodies (1:1000, Cell Signaling Technology) for 1 h at room temperature. Nuclei were counter-stained with DAPI. Images were captured and analyzed using a DS-Ri2 fluorescence microscope (Nikon, Tokyo, Japan).
Western blot analysis
Cells cultured on dishes were washed using cold PBS and lysed with RIPA Lysis Buffer (Thermo Fisher Scientific, Waltham, MA, USA) in the presence of protease and phosphatase inhibitors (Thermo Fisher Scientific) on ice for 30 min. For muscle tissue preparation, samples were disrupted with a Tissue Lyser II (Qiagen, Hilden, Germany) using RIPA Lysis Buffer supplemented with protease and phosphatase inhibitors as well as 0.5 M EDTA (Invitrogen), followed by a 30-min incubation on ice with intermittent vortexing. The lysates from cultured cells or muscle tissues were ultrasonicated, centrifuged at 12,000×g for 30 min at 4 °C, and the soluble protein supernatant was collected. The total protein concentration was measured using a Pierce BCA Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Samples containing identical amounts of protein (30 μg) were loaded and run in 10% (w/v) sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels (Invitrogen).For detecting dystrophin, 6% SDS-PAGE gels were used. Then the proteins were transferred to 0.45 μm pore-sized polyvinylidene difluoride (PVDF) membranes (Merck Millipore). The membranes were blocked with 5% (w/v) BSA in Tris-buffered saline with Tween 20 (TBS/T) (Sigma-Aldrich) for 1 h at room temperature, and incubated overnight at 4 °C with primary antibodies as follows: PAX7 (1:500, Developmental Studies Hybridoma Bank), MYF5 (1:500, Abcam), Desmin (1:1000, Abcam), MF20 (1:500, Developmental Studies Hybridoma Bank), DYS1 (1:200, Leica Biosystems, Wetzlar, Germany), GAPDH (1:1000, Cell Signaling Technology), and β-Tubulin (1:1000, Cell Signaling Technology). Membranes were washed three times with TBS/T and incubated with anti-rabbit or anti-mouse HRP-linked secondary antibodies (1:1000, Cell Signaling Technology) for 1 h at room temperature. Proteins were visualized using the immobilon western chemiluminescent HRP substrate (Merck Millipore) and an ImageQuant LAS 4000 detection system (GE Healthcare Life Sciences, Chicago, IL, USA). Protein expression levels were normalized to GAPDH or β-Tubulin and quantified using Image J software.
Hematoxylin and eosin staining of muscle tissue sections
Hematoxylin and eosin (H&E) staining was performed to detect the pathological lesions of muscles. Serial 10-μm-thick cryosections of muscle tissues were collected, fixed with cold acetone for 10 min at 4 °C. Cryosections were stained with the haematoxylin for nuclei staining for 4 min, rinsed in running tap water, differentiated with 1% acid alcohol for 2 s, rinsed in running tap water again, and then rinsed in Scott’s tap water substitute for blueing up for 20 s and rinsed in running tap water. Cryosections were stained with eosin for 2 min, dehydrated, cleared, and mounted with neutral resins.
All data are presented as mean ± standard error of the mean (SEM) and statistically analyzed by GraphPad Prism. Differences between two groups of samples were assessed using two-tailed Student’s t test while the one-way analysis of variance (ANOVA) was used for multiple comparison between groups. P < 0.05 was considered statistically significant.
Retention of pluripotent characterization on EGFP hiPSCs
To facilitate tracking of transplanted hiPSC-derived myogenic progenitors, a lentivirus vector overexpressing green fluorescent protein (GFP) was constructed (Additional file 1: Figure S1) and transfected into healthy control hiPSCs. After puromycin selection for 14 days, the majority of cells (> 90%) were infected, as shown by GFP expression (Fig. 1a). GFP-positive colonies were selected, maintained, and used for further experiments. The morphology of EGFP hiPSCs resembled that of untransfected hiPSCs (Fig. 1a) and could be passaged as usual with normal karyotype (Fig. 1b). To further test whether EGFP hiPSCs retained pluripotent characterization, analysis of pluripotency markers was performed and EGFP hiPSCs were induced to differentiate into three germ layers in vitro and in vivo. Immunocytochemistry studies showed that EGFP hiPSCs expressed pluripotency markers, such as OCT4, SOX2, TRA-1-60, and TRA-1-81 (Fig. 1c). Accordingly, the negative control experiments of immunocytochemistry on iPSCs showed that no unspecific immunofluorescence was detected on secondary antibodies without primary antibody (Additional file 1: Figure S2). Similar to untransfected hiPSCs, EGFP hiPSCs could form EBs containing three germ layers in vitro, and expressed specific markers of endoderm (AFP), mesoderm (αSMA), and ectoderm (nestin) (Fig. 1d). Furthermore, 2 months after EGFP hiPSCs were subcutaneously injected into NOD SCID mice, teratoma formation was detected and analyzed. Our histological examination revealed that teratomas contained tissues of three germ layers, including glandular epithelium (endoderm), smooth muscle (mesoderm), and neural tube (ectoderm) (Fig. 1e). These results demonstrate that EGFP hiPSCs harbored the pluripotent stem cell features of self-renewal and multipotential differentiation.
Myogenic differentiation from EGFP hiPSCs in vitro
In an earlier study, we showed that engraftable myogenic progenitors could be effectively generated from mouse ADSCs with supplementation of the small molecules including BIO, forskolin and bFGF . The differentiation procedure to obtain robust myogenic progenitors and the terminal myofibers from EGFP hiPSCswas showed in Fig. 2a and Additional file 1: Figure S3. Immunofluorescence analyses revealed robust expression of the early myogenic markers PAX7 and MYF5, as well as Myogenin and MyoD1 at differentiation day 14 (Fig. 2b and Additional file 1: Figure S4). At differentiation day 36, the expression of late skeletal muscle markers desmin, MHC, and dystrophin were detected, indicating maturation of myogenic progenitors within the culture (Fig. 2c). Moreover, we evaluated the expression of each myogenic marker at different time points during myogenic differentiation using western blot analyses. The results demonstrated that the amount of PAX7 peaked on day 8 and then gradually decreased (Fig. 2d). We also found that the amount of MYF5 and desmin kept increasing during differentiation process, while that of MHC and dystrophin increased from day 36 and day 28, respectively (Fig. 2d). Satellite cells are regarded as the preferable cell type for cell transplantation therapy because of their self-renewal and muscle regeneration potential, and Pax7 is the crucial myogenic transcriptional factor specifically expressed in satellite cells. Therefore, myogenic differentiation day 8 was chosen as the most suitable timepoint for transplantation of EGFP hiPSC-derived myogenic progenitors into mdx mice because of the peak expression level of PAX7.
Intramuscular transplantation of EGFP hiPSC-derived myogenic progenitors restore dystrophin expression in mdx mice
To investigate the muscle regenerative potential of EGFP hiPSC-derived myogenic progenitors in vivo, cells were transplanted into mdx mice, a DMD mouse model characterized by lacking dystrophin expression. We confirmed that the mdx mice used as recipients were deficient in dystrophin expression compared to that found in the muscles of normal C57 mice (Data not shown). At 4 weeks after transplantation, dystrophin-positive myofibers regenerated from EGFP hiPSC-derived myogenic progenitors (expressing GFP) were detected in cell-transplanted left TA muscles as well as PBS-injected right TA muscles, while just few reversed myofibers was observed in mdx mice that received PBS in both TA muscles (Fig. 3a). Quantitative analysis showed that the number of dystrophin-positive myofibers per TA section in negative control muscles, PBS-injected muscles, and cell-injected muscles were 1.80 ± 1.11, 37.40 ± 4.45, 59.00 ± 3.99, respectively (Fig. 3d). In addition, 8 weeks after transplantation, resemble muscle engraftment as 4 weeks was observed in both cell-transplanted and PBS-injected TA muscles as demonstrated by the number of myofibers co-expressing GFP and dystrophin (Fig. 3b). Quantitative analysis showed that the number of dystrophin-positive myofibers per TA section in negative control muscles, PBS-injected muscles, and cell-injected muscles were 2.00 ± 1.30, 60.60 ± 1.86, 91.20 ± 4.72, respectively (Fig. 3d).
Long-term engraftment and dystrophin protein restoration have been observed in several studies by transplanting mouse ADSC-derived myogenic progenitors , human mesenchymal stem cells (MSCs) , or mouse bone marrow-derived cells  into mdx mice, while long-term muscle incorporation after transplantation of hiPSC/hESC-derived cells into mdx mice has not been previously investigated. In the present study, to further test whether the myogenic progenitors differentiated from EGFP hiPSCs could contribute to long-term engraftment, we prolonged the observation duration to 12 weeks after intramuscular transplantation. Notably, we identified a considerable number of dystrophin-positive myofibers derived from GFP-expressing donor cells in the left TA muscles that received cells (121.80 ± 8.35) (Fig. 3c and Additional file 1: Figure S5) as well as the contralateral TA muscles that received PBS (61.80 ± 5.23) (Data not shown). It is noteworthy that quantitative analysis dystrophin-positive myofibers showed the number of dystrophin-positive myofibers in cell-injected muscles at 8 weeks after transplantation was higher than that at 4 weeks (P < 0.01), and the number of dystrophin-positive myofibers at 12 weeks after transplantation was higher than that at 8 weeks (P < 0.01) (Fig. 3d). In the mdx mice received cell injection, we detected the expression of human spectrin, indicating human cell derived myofibers (Additional file 1: Figure S6). Overall, our results strongly indicated that intramuscular transplantation of EGFP hiPSC-derived myogenic progenitors were competent to engraft into the muscles of mdx mice and restore dystrophin expression. Meanwhile, the number of dystrophin positive myofibers in cell-injected muscles increased along with the engrafted time went by.
EGFP hiPSC-derived myogenic progenitors engrafted into the muscles of mdx mice via systemic transplantation
Systemic transplantation of iPSC-derived myogenic progenitors has not been previously performed in dystrophic mouse models. To determine whether EGFP hiPSC-derived myogenic progenitors transplanted into mdx mice through tail vein injection are capable to fuse into host myofibers and contribute to dystrophin restoration, cells at myogenic differentiation day 8 were injected into mdx mice via tail vein, while a group of mdx mice received the same volume of PBS as controls. At 8 weeks after intravenous transplantation, all mdx mice received cells or PBS were alive and showed no functional changes on gait and rotarod test prior to sample collection (data not shown). No tumor formation was found in mdx mice received cells transplantation (data not shown). We found that few detectable dystrophin-positive fibers without GFP was observed in TA muscles. In contrast, significant engraftment of transplanted cells was detected in TA muscles from mdx mice with systemic transplantation of EGFP hiPSC-derived myogenic progenitors, as demonstrated by the presence of robust GFP and dystrophin double-positive myofibers (Fig. 4a and Additional file 1: Figure S7). Quantitative analysis revealed that dystrophin-positive myofibers per TA section in cell-transplanted mdx mice was significantly higher than that in negative control mdx mice (84.60 ± 3.84 vs. 1.00 ± 0.55 respectively, P < 0.001) (Fig. 4b). No GFP positive cells were detected in other organs like heart and liver (data not shown). Our results indicated that myogenic progenitors transplanted by intravenous injection can be recruited to engraft into dystrophin-deficient muscles and fuse to regenerate donor cell-derived myofibers, thereby resulting in dystrophin restoration in vivo.
EGFP hiPSC-derived myogenic progenitors treatment ameliorate pathological lesions in mdx mice
An increased number of central nuclear myofibers (CNFs) is one of remarkable pathological characteristics in the muscles of DMD. In the intramuscular transplantation experiment, 8 weeks after cell transplantation, H&E staining analysis revealed that the ratio of CNFs in TA muscles of negative control mdx mice was up to 70.64% ± 2.35%, while the percentage of CNFs in TA muscles received cell-injection and contralateral PBS-injected TA muscles decreased significantly (39.82% ± 2.38 and 56.20% ± 3.36%, respectively) (Fig. 5a, c). For systemic transplantation therapy, H&E staining analysis indicated that the percentage of CNFs in TA muscles of mdx mice with intravenous cell injection (38.75% ± 1.74%) decreased compared to that in TA muscles of mdx mice with PBS injection (64.90% ± 2.72%) (Fig. 5b, d). As a matter of concern on therapeutic application of stem cell transplantation, we also evaluated the muscle regenerative potential of hiPSCs-derived myogenic progenitors without transfecting EGFP. Similarly, at 8 weeks after systemic transplantation, H&E staining analysis indicated that the ratio of CNFs number in TA muscles of mdx mice with intravenous cell injection (23.07% ± 1.68%) decreased significantly compared to that of mdx mice with injecting PBS intravenously (51.33% ± 3.13%) (Additional file 1: Figure S8).
EGFP hiPSC-derived myogenic progenitors contribute to the satellite cell compartment
To examine whether EGFP hiPSC-derived myogenic progenitors are endowed with the ability to undergo self-renewal and contribute to the satellite cell compartment, immunofluorescence analyses of the satellite cell specific marker PAX7 were performed. At 8 weeks after intramuscular transplantation, we found that GFP and PAX7 double-positive cells were observed around the engrafted myofibers in TA muscles that received cells as well as their counterparts injected with PBS in the same mdx mice (Fig. 6a), a finding which suggests donor cell-derived satellite cells can replenish the satellite cell pool in host muscles. In contrast, no satellite cell engraftment was detected in negative control mdx mice that received PBS in both TA muscles, as demonstrated by the sole presence of host-originated satellite cells, which are PAX7-positive cells lacking GFP expression (Fig. 6a). Similarly, at 8 weeks after intravenous transplantation, PAX7 and GFP double positive nuclei were detected in TA muscles of mdx mice received cell injection but not found in mdx mice injected with PBS (Fig. 6b). Our results demonstrated that transplantation of EGFP hiPSC-derived myogenic progenitors contribute to seed the satellite cell pool.
DMD is characterized by deficient muscular dystrophin protein and repeated rounds of skeletal muscle degeneration and regeneration leading to the exhaustion of myogenic stem cells . There are no effective treatments for DMD patients to date, and pharmacological treatments such as glucocorticoid administration are insufficient to improve the disease phenotype and reverse its devastating prognosis . More effective potential therapeutic strategies, including cell-based therapy, gene therapy as well as exon skipping, have been evaluated on DMD animal models and have undergone clinical trials . For successful stem cell-based therapies, transplanted cells expressing functional dystrophin protein should be able to fuse with recipient myofibers, participate in muscle regeneration, and ideally replenish satellite cell pool to support long-term engraftment . In addition to myoblasts or satellite cells which are initially utilized for transplantation in mdx mice and DMD patients, other adult stem cells including mesoangioblasts, CD133+ cells, and bone marrow-derived cells have been shown to exert muscle regeneration potential in vivo . Although transplantations using these adult stem cells show apparent engraftment in mdx mice, their clinical application is hindered by their limited ability for expansion ex vivo, poor survival, and reduced migration after transplantation [11, 24, 27]. Notably, ESCs/iPSCs overcome many of these disadvantages due to their virtually unlimited number of donor derived cells for muscle repair. Furthermore, ESC/iPSC-derived myogenic progenitors exhibit higher proliferative and migration ability than those derived from adult stem cell [44, 45]. However, most studies using ESCs/iPSCs to generate myogenic progenitors rely on overexpression of transcription factors MyoD or Pax7 before transplantation, with an inherent risk of insertional mutagenesis rendering these cells unsuitable for clinical use .
In the present study, we generated healthy donor-derived hiPSCs expressing EGFP in order to track donor cells in vivo and demonstrated that they efficiently differentiate into myogenic progenitors in a serum-free culture system with the induction of small molecules. Myogenic differentiation from hiPSCs using the defined medium containing BIO, bFGF, and forskolin had been reported in a previous study, but the muscle regeneration potential of these hiPSC-derived myogenic progenitors has not been evaluated in mdx mice . Our previous work showed that myogenic progenitors differentiated from mouse ADSCs with the treatment of these three molecules could contribute to long-term engraftment in the muscles of mdx mice . Interestingly, in the present study, the peak point of Pax7 expression (day8) during myogenic differentiation is earlier than previous work (day14), suggesting distinct myogenic induction efficiency between cell types or cell lines. Similarly, we demonstrated that EGFP hiPSC-derived myogenic progenitors could process maturation in vitro and differentiate into myotubes expressing the late skeletal muscle markers desmin, MHC, and dystrophin, with the absence of Pax7 expression.
Our in vivo cell transplantation studies demonstrated successful incorporation of EGFP hiPSC-derived myogenic progenitors in intramuscular injected mdx mice pre-treated with immunosuppressant Busulfex. Herein, we detected engraftment contributions to myofiber regeneration and restoration of dystrophin expression in recipient muscles, and the donor cell-derived myofiber engraftment was observed up to 12 weeks. It is notable that other studies point out that the embryonic origin of ESC/iPSC-derived progenitors makes them more suitable for cell replacement therapy due to their capacity of expansion and migration . This may explain why we detected donor engraftments in the PBS-injected TA muscles that were contralateral to the cell-injected muscles. While this may raise safety concerns, we were unable to detect any teratomas in any cell injected mice. The chemokine receptor CXCR4 is highly expressed in satellite cells as well as cultured myogenic progenitors, while its ligand CXCL12 is overexpressed in dystrophic muscles . CXCL12/CXCR4 signaling plays an essential role in migration of muscle cells and efficient muscle regeneration [48,49,50]. This suggests a circulatory migratory recruitment mechanism that explains the contralateral detection in PBS-injected muscles that merits further studies.
Because whole-body muscles are affected in DMD patients, the desirable engrafted cells should be able to cross the blood barrier to allow more general systemic delivery. Myogenic progenitors obtained from mouse iPSCs , CD133+ cells , and SP cells  as well as mesoangioblasts  have shown significant myofiber engraftment following intravenous or intra-arterial transplantation, making systemic delivery a promising transplanting strategy for cell-based therapy in future clinical application. Similarly our previous study showed that intravenous transplantation of myogenic progenitors derived from ADSCs using BIO, bFGF and forskolin cocktail induction protocol resulted in considerable muscle engraftment in mdx mice . The present study expanded these observations by systemically delivering EGFP hiPSC-derived myogenic progenitors. These successfully contributed to significant muscle regeneration and restored dystrophin expression, as shown by GFP/dystrophin double positive myofibers in cell-injected mdx mice, suggesting that transplanted cells in circulation were recruited and inhabited within deficient host muscles . Importantly, no tumor formation was observed during transplantation, which confirmed the safety of systemic delivery as a potential therapeutic strategy for clinical use. Furthermore, as a matter of increasing concern in modern clinical therapeutics, it is of great value to assess muscle regeneration potential of hiPSC-derived myogenic progenitors in female animal models. When transplanting male hiPSC-derived myogenic progenitors into female mdx mice, the detection of Y chromosome in the muscle of female receptor could be utilized to evaluate the donor cell-derived myofiber engraftment. Further studies are needed to investigate the feasibility of transplanting male-derived stem cells into female animal models. It is demonstrated that the intrinsic satellite cell dysfunction plays an essential role in pathological progression of DMD . In mdx muscles, dystrophin deficiency impairs polarity and subsequent asymmetric cell division of satellite cells resulting in reduced myogenic potential and loss of muscle regenerative capacity [8, 53]. Along these lines, it is conceivable that engraftment of functional satellite-like cells would contribute to muscle regeneration by replenishing satellite cell pool in mdx mice. Furthermore, restoration of dystrophin protein transplanted cells may facilitate intrinsic satellite cells to undergo myogenic commitment and enhance muscle repair. In the present study, we showed that EGFP hiPSC-derived myogenic progenitors using non-transgenic induction protocol incorporated into satellite cell compartment, likely improving crucial and sustainable myofiber regeneration and restoration of dystrophin. Supporting these observations, consistent dystrophin expression was observed in PAX7 and GFP double positive satellite transplanted cells. The presence of donor cell-derived myofibers and satellite cells support that transplanted myogenic progenitors migrate into circulatory system, and are recruited by dystrophic muscles.
We generated healthy donor hiPSCs-derived transgene-free and serum-free myogenic progenitors which were capable of engrafting into host myofibers, participate in muscle regeneration, restore dystrophin expression, and replenish satellite cell niche following intramuscular transplantation into mdx mice. Furthermore, we demonstrated that these myogenic progenitors can also be delivered by intravenous transplantation to contribute to muscle engraftment, with significant implications for the development of cell-based therapeutics in DMD patients.
Availability of data and materials
All data generated or analysed during this study are included in this published article.
Duchenne muscular dystrophy
Induced pluripotent stem cells
Enhanced green fluorescent protein
Paired-box transcription factor 7
Adipose-derived stem cells
Embryonic stem cells
Glycogen synthase kinase-3β
Basic fibroblast growth factor
Bone morphogenic protein
Dulbecco’s Modified Eagle’s medium
Myosin heavy chain
Central nuclear myofibers
Hoffman EP, Brown RJ, Kunkel LM. Dystrophin: the protein product of the duchenne muscular dystrophy locus. Cell. 1987;51(6):919–28.
Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845–60.
Bhatnagar S, Kumar A. Therapeutic targeting of signaling pathways in muscular dystrophy. J Mol Med (Berl). 2010;88(2):155–66.
Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20(10):18168–84.
Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther. 2007;15(5):867–77.
Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve. 2013;47(5):649–63.
Almada AE, Wagers AJ. Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease. Nat Rev Mol Cell Biol. 2016;17(5):267–79.
Dumont NA, Wang YX, von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21(12):1455–63.
Chang NC, Chevalier FP, Rudnicki MA. Satellite cells in muscular dystrophy—lost in polarity. Trends Mol Med. 2016;22(6):479–96.
Reinig AM, Mirzaei S, Berlau DJ. Advances in the treatment of duchenne muscular dystrophy: new and emerging pharmacotherapies. Pharmacotherapy. 2017;37(4):492–9.
Bajek A, Porowinska D, Kloskowski T, Brzoska E, Ciemerych MA, Drewa T. Cell therapy in duchenne muscular dystrophy treatment: clinical trials overview. Crit Rev Eukaryot Gene Expr. 2015;25(1):1–11.
Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of Mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature. 1989;337(6203):176–9.
Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, et al. Myoblast transfer in the treatment of Duchenne’s muscular dystrophy. N Engl J Med. 1995;333(13):832–8.
Skuk D, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, et al. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol. 2006;65(4):371–86.
Skuk D, Goulet M, Roy B, Piette V, Cote CH, Chapdelaine P, et al. First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord. 2007;17(1):38–46.
Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science. 2005;309(5743):2064–7.
Bachrach E, Perez AL, Choi YH, Illigens BM, Jun SJ, Del NP, et al. Muscle engraftment of myogenic progenitor cells following intraarterial transplantation. Muscle Nerve. 2006;34(1):44–52.
Benchaouir R, Meregalli M, Farini A, D’Antona G, Belicchi M, Goyenvalle A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered Dmd patient stem cells into dystrophic mice. Cell Stem Cell. 2007;1(6):646–57.
Torrente Y, Belicchi M, Marchesi C, D’Antona G, Cogiamanian F, Pisati F, et al. Autologous transplantation of muscle-derived Cd133+ stem cells in duchenne muscle patients. Cell Transplant. 2007;16(6):563–77.
Sampaolesi M, Blot S, D’Antona G, Granger N, Tonlorenzi R, Innocenzi A, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature. 2006;444(7119):574–9.
Vieira NM, Valadares M, Zucconi E, Secco M, Bueno CJ, Brandalise V, et al. human adipose-derived mesenchymal stromal cells injected systemically into Grmd dogs without immunosuppression are able to reach the host muscle and express human dystrophin. Cell Transplant. 2012;21(7):1407–17.
Zhang Y, Zhu Y, Li Y, Cao J, Zhang H, Chen M, et al. Long-term engraftment of myogenic progenitors from adipose-derived stem cells and muscle regeneration in dystrophic mice. Hum Mol Genet. 2015;24(21):6029–40.
Galli R, Borello U, Gritti A, Minasi MG, Bjornson C, Coletta M, et al. Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci. 2000;3(10):986–91.
Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y. Stem cell therapies to treat muscular dystrophy: progress to date. Biodrugs. 2010;24(4):237–47.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.
Rinaldi F, Perlingeiro RC. Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks. Transl Res. 2014;163(4):409–17.
Abujarour R, Valamehr B. Generation of skeletal muscle cells from pluripotent stem cells: advances and challenges. Front Cell Dev Biol. 2015;3:29.
Abujarour R, Valamehr B, Robinson M, Rezner B, Vranceanu F, Flynn P. Optimized surface markers for the prospective isolation of high-quality hipscs using flow cytometry selection. Sci Rep. 2013;3:1179.
Darabi R, Arpke RW, Irion S, Dimos JT, Grskovic M, Kyba M, et al. Human Es- and Ips-derived myogenic progenitors restore dystrophin and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell. 2012;10(5):610–9.
Darabi R, Pan W, Bosnakovski D, Baik J, Kyba M, Perlingeiro RC. Functional myogenic engraftment from mouse Ips cells. Stem Cell Rev. 2011;7(4):948–57.
Abujarour R, Bennett M, Valamehr B, Lee TT, Robinson M, Robbins D, et al. Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Stem Cells Transl Med. 2014;3(2):149–60.
Feng Cai W, Huang W, Wang L, Wang JP, Zhang L, Ashraf M, et al. Induced pluripotent stem cells derived muscle progenitors effectively mitigate muscular dystrophy through restoring the dystrophin distribution. J Stem Cell Res Ther. 2016;6:10.
Borchin B, Chen J, Barberi T. Derivation and facs-mediated purification of Pax3+/Pax7+ skeletal muscle precursors from human pluripotent stem cells. Stem Cell Rep. 2013;1(6):620–31.
Shelton M, Metz J, Liu J, Carpenedo RL, Demers SP, Stanford WL, et al. Derivation and expansion of Pax7-positive muscle progenitors from human and mouse embryonic stem cells. Stem Cell Rep. 2014;3(3):516–29.
Xu C, Tabebordbar M, Iovino S, Ciarlo C, Liu J, Castiglioni A, et al. A zebrafish embryo culture system defines factors that promote vertebrate myogenesis across species. Cell. 2013;155(4):909–21.
Hosoyama T, McGivern JV, Van Dyke JM, Ebert AD, Suzuki M. Derivation of myogenic progenitors directly from human pluripotent stem cells using a sphere-based culture. Plos ONE. 2014;3(5):564–74.
Chal J, Oginuma M, Al TZ, Gobert B, Sumara O, Hick A, et al. Differentiation of pluripotent stem cells to muscle fiber to model duchenne muscular dystrophy. Nat Biotechnol. 2015;33(9):962–9.
Chal J, Al Tanoury Z, Hestin M, Gobert B, Aivio S, Hick A, et al. Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro. Nat Biotechnol. 2016;11(10):1833–50.
Li Y, Cao J, Chen M, Li J, Sun Y, Zhang Y, et al. Abnormal neural progenitor cells differentiated from induced pluripotent stem cells partially mimicked development of Tsc2 neurological abnormalities. Stem Cell Rep. 2017;8(4):883–93.
Chan J, Waddington SN, O’Donoghue K, Kurata H, Guillot PV, Gotherstrom C, et al. Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic Mdx mouse. Stem Cells. 2007;25(4):875–84.
Wernig G, Janzen V, Schafer R, Zweyer M, Knauf U, Hoegemeier O, et al. The vast majority of bone-marrow-derived cells integrated into Mdx muscle fibers are silent despite long-term engraftment. Proc Natl Acad Sci USA. 2005;102(33):11852–7.
Filareto A, Darabi R, Perlingeiro RC. Engraftment of Es-derived myogenic progenitors in a severe mouse model of muscular dystrophy. J Stem Cell Res Ther. 2012;10:1.
Roca I, Requena J, Edel MJ, Alvarez-Palomo AB. Myogenic precursors from Ips cells for skeletal muscle cell replacement therapy. J Clin Med. 2015;4(2):243–59.
Barberi T, Bradbury M, Dincer Z, Panagiotakos G, Socci ND, Studer L. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med. 2007;13(5):642–8.
Kodaka Y, Rabu G, Asakura A. Skeletal muscle cell induction from pluripotent stem cells. Stem Cells Int. 2017;2017:1376151.
Perez AL, Bachrach E, Illigens BM, Jun SJ, Bagden E, Steffen L, et al. Cxcr4 enhances engraftment of muscle progenitor cells. Muscle Nerve. 2009;40(4):562–72.
Griffin CA, Apponi LH, Long KK, Pavlath GK. Chemokine expression and control of muscle cell migration during myogenesis. J Cell Sci. 2010;123(Pt 18):3052–60.
Kowalski K, Kolodziejczyk A, Sikorska M, Placzkiewicz J, Cichosz P, Kowalewska M, et al. Stem cells migration during skeletal muscle regeneration—the role of Sdf-1/Cxcr4 and Sdf-1/Cxcr7 axis. Cell Adh Migr. 2017;11(4):384–98.
Maeda Y, Yonemochi Y, Nakajyo Y, Hidaka H, Ikeda T, Ando Y. Cxcl12 and osteopontin from bone marrow-derived mesenchymal stromal cells improve muscle regeneration. Sci Rep. 2017;7(1):3305.
Filareto A, Parker S, Darabi R, Borges L, Iacovino M, Schaaf T, et al. An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun. 2013;4:1549.
Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, et al. Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc Natl Acad Sci USA. 2004;101(10):3581–6.
Biressi S, Miyabara EH, Gopinath SD, Carlig PM, Rando TA. A Wnt-Tgfbeta2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci Transl Med. 2014;6(267):176r–267r.
This work was supported by the Young Scientist Fund of National Natural Science Foundation of China (No. 81601087); the National Natural Science Foundation of China (No. 81471280 and 81771359); the Postdoctoral Science Foundation of China (No. 2019M663279); the Guangzhou Science and Technology Program (No. 1561000153);the Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases (No. 2014B030301035); the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases (No. 2015B050501003);the Guangdong Provincial Engineering Center for Major Neurological Disease Treatment; Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease, and Guangdong Provincial Clinical Research Center for Neurological Diseases.
Ethics approval and consent to participate
All procedures performed in studies were approved by the Ethics Committee at the First Affiliated Hospital of Sun Yat-sen University and in accordance with the Helsinki declaration and its later amendments or comparable ethical standards.
Consent for publication
All the authors consent to publish this manuscript.
The authors declare that they have no conflicts of interests.
Schematic diagram of construction of the lentiviral vector pLV/Final-Puro-EF1α-EGFP. The entry vectors, pUp-EF1α and pDown-EGFP were generated and recombined into the pDes-Puro vector utilizing the recognized LR reaction protocol.
The negative control of immunocytochemistry analysis on iPSCs. No unspecific immunofluorescence was detected on Alexa Fluor 555-conjugated anti-mouse secondary antibodies (upper panle) and Alexa Fluor 555-conjugated anti-rabbit secondary antibodies (lower panle) without primary antibody.
Representative phase contrast (A-E) and matching GFP fluorescence (F-J) images during myogenic differentiation at several time points. (A, F) EGFP hiPSC colonies at day 0. (B, G) EBs in suspension culture at day 4. (C, H) EB-derived monolayer cells at day 10 after plating EBs on Matrigel-coated plates. (D, I) proliferating monolayer of myogenic progenitors at day 14. (E, J) spindle-shaped myocytes at day 36. Scale bars = 100 μm.
Immunofluorescence analysis indicated expression of myogenic markers Myogenin and MyoD1 at differentiation day 14. Scale bars = 100 μm.
Immunofluorescence analysis showed no expression of dystrophin (red) and GFP (green) in TA muscles of negative control mdx mice (upper panels), while dystrophin and GFP double expression in PBS-injected right TA muscles (middle panels) and cell-transplanted left TA muscles (lower panels) at 12 weeks after transplantation. Scale bars = 200 μm.
At 12 weeks after transplantation, immunofluorescence assays showed the expression of human spectrin in the cell-transplanted left TA muscles as well as contralateral muscles. Western blot analysis confirmed the expression of human spectrin. Scale bars = 400 μm.
Immunofluorescence assays showed no dystrophin and GFP expression was observed in the muscles of negative control mdx mice (upper panel), while the expression of dystrophin (red) and GFP (green) in the intravenously-injected TA muscles (lower panel) was detected after 8 weeks of transplantation. Scale bars = 200 μm.
Systemic transplantation of hiPSC-derived myogenic progenitors without transfecting EGFP reduced the ratio of central nuclei myofibers (CNFs) in mdx mice. (A) H&E staining showed representative images of TA muscles in mdx mice received PBS (left) and cells (right) at 8 weeks after intravenous transplantation. (B) Quantitative analysis indicated the percentage of CNFs for each group at 8 weeks after intravenous transplantation. 5 random sections for each muscle were examined. **P < 0.01, Scale bars = 400 μm.
About this article
Cite this article
He, R., Li, H., Wang, L. et al. Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy. Biol Res 53, 22 (2020). https://doi.org/10.1186/s40659-020-00288-1
- Duchenne muscular dystrophy
- Human induced pluripotent stem cells
- Myogenic progenitors
- Muscle regeneration
- Satellite cells